Premium
FEIBA prophylaxis for patients with haemophilia and inhibitors
Author(s) -
VALENTINO L. A.
Publication year - 2006
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2006.01382.x
Subject(s) - medicine , haemophilia , clotting factor , venous access , factor ix , arthropathy , complication , haemophilia a , quality of life (healthcare) , haemophilia b , disease , surgery , intensive care medicine , osteoarthritis , catheter , alternative medicine , nursing , pathology
Summary. Prophylaxis with clotting factor concentrates has been shown to prevent bleeding episodes and improve quality of life in patients with severe haemophilia A or B. The benefits of long‐term prophylaxis may also extend to patients with high‐titre factor VIII or IX inhibitors who have failed or are not candidates for immune tolerance. Because the presence of an alloantibody makes it difficult to achieve haemostasis during a bleeding event, inhibitor patients are at increased risk for life‐threatening haemorrhage and the development of arthropathy. Accumulating evidence suggests that prophylactic therapy with the bypassing agent FEIBA reduces bleeding episodes, including haemarthrosis, and maintains normal joints, although it does not halt established joint disease. Infections associated with central venous access devices are a frequent complication of prophylaxis in young children with haemophilia.